Professor Janet Shipley is Head of the Division of Molecular Pathology and leads the Sarcoma Molecular Pathology Team at the The Institute of Cancer Research, London. 

Originally from Newcastle upon Tyne, Professor Shipley obtained her PhD from the University of London. She joined ICR following previous laboratory experience at the Paediatric Research Unit at Guy’s Hospital, the Genetics Division of Harvard Medical School, Boston US and the Imperial Cancer Research Fund (now the Crick).

She has been awarded Fellowship of the Royal College of Pathologists (FRCPath). She is a member of the National Cancer Research Institute (NCRI) Clinical Studies Young Onset Sarcoma Subgroup (YOSS), she chairs the Biological Committee for the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) and is Biology Lead in the current international trial for Frontline and Relapse Rhabdomyosarcoma patients (FaR-RMS).

Her research is focused on identifying molecular markers of high-risk in young onset sarcomas and understanding associated molecular mechanisms in order to derive novel treatments for these patients. 

Robin Jones is a medical oncologist with a specialist interest in bone and soft issue sarcomas. He has been principle investigator on numerous phase I, II and III trials.

He completed his medical training at Guy’s and St Thomas’ Hospital, and his oncology training at The Royal Marsden. His postgraduate research degree, with Professor Dowsett at the ICR, evaluated potential predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy.

He is Consultant Medical Oncologist and Professor at the Royal Marsden and the ICR. He has been a leading investigator on a number of trials of investigational agents in sarcomas, including trials that led to the FDA approval of avapritinib, ripretinib, trabectedin and tazemetostat. An ongoing collaboration with Dr Paul Huang focuses on translational studies in sarcomas. He is a board member of the Connective Tissue Oncology Society (CTOS) and has served as scientific committee member for the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), American Joint Committee on Cancer (AJCC) and Sarcoma Alliance for Research through Collaboration (SARC).

Dr Paul Huang leads the Molecular and Systems Oncology Team in the Division of Molecular Pathology at the Institute of Cancer Research, London. 

Dr Huang received his PhD in Biological Engineering from Massachusetts Institute of Technology and joined the ICR in 2009. He is currently a tenured Faculty member and Reader in Molecular & Translational Oncology and holds a Cancer Research UK Career Establishment Award.

His laboratory focuses on understanding aberrant signalling networks and drug resistance in sarcomas, with the goal of developing biomarkers and new therapies for this complex group of rare diseases.

He serves as Vice Chair of the Pathology & Translational Research Committee of the EORTC Soft Tissue and Bone Sarcoma Group and as a member of several panels including the NCRI Sarcoma Clinical Studies Group, the NCRI Cellular Molecular Pathology (CM-Path) Clinical Trial Pathology Advisory Group (CT-PAG) and Research Advisory Committee of Sarcoma UK. He was elected a Fellow of the Royal Society of Biology in 2020.